Diebold Nixdorf (DBD) Misses Q2 EPS by 23c, Lowers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts DBD Hot Sheet
Price: $57.98 --0%
Financial Fact:
Income from continuing operations, net of tax: -21.6M
Today's EPS Names:
KTB, CABO, FDUS, More
Financial Fact:
Income from continuing operations, net of tax: -21.6M
Today's EPS Names:
KTB, CABO, FDUS, More
Join SI Premium – FREE
Diebold Nixdorf (NYSE: DBD) reported Q2 EPS of ($0.21), $0.23 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.1 billion.
GUIDANCE:
Diebold Nixdorf sees FY2018 revenue of $4.5 billion, versus the consensus of $4.61 billion.
- Net Income (Loss) $(365 million) - $(325 million)
For earnings history and earnings-related data on Diebold Nixdorf (DBD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- Ecovyst Inc. (ECVT) Tops Q3 EPS by 2c
- Myriad Genetics (MYGN) Tops Q3 EPS by 9c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
